Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Gökbuget, Nicola; Dombret, Hervé; Bonifacio, Massimiliano; Reichle, Albrecht; Graux, Carlos; Faul, Christoph; Diedrich, H.; S. Topp, Max; Brüggemann, Monika; Horst, Heinz‐August; Havelange, Violaine; Stieglmaier, Julia; Wessels, Hendrik; Haddad, Vincent; E. Benjamin, Jonathan; Zugmaier, Gerhard; Nagorsen, Dirk; C. Bargou, Ralf

doi:10.1182/blood-2017-08-798322

Public

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Published in Blood • Apr 5, 2018

Authors:

Nicola Gökbuget

Hervé Dombret

Massimiliano Bonifacio

Abstract

Abstract Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase–polymerase chain reaction or flow cytometry. MRD is the strongest predictor of relapse in ALL...

Subject

Blinatumomab

Minimal residual disease

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!